{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"70"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"199"}],"units":"Participants"}],"description":"A progressive disease confirmed by a CT scan.","groups":[{"description":"This was a multicenter, open-label, monotherapy, long-term extension study designed to evaluate the long-term (\\> 6 months) safety and tolerability of a fixed daily dosing regimen of ibrutinib. PCI-32765: Dose based on parent protocol CLL: chronic lymphocytic leukemia/ SLL: small lymphocytic lymphoma.","id":"OG000","title":"IBRUTINIB/PCI-32765"}],"paramType":"COUNT_OF_PARTICIPANTS","reportingStatus":"POSTED","timeFrame":"30 days after last dose of study drug, continue up to 6 months","title":"Progressive Disease (PD)","type":"SECONDARY","unitOfMeasure":"Participants"}